Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability.

Larry K Golightly, Gerard R Barber, Michelle A Barron, Robert L Page
{"title":"Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability.","authors":"Larry K Golightly,&nbsp;Gerard R Barber,&nbsp;Michelle A Barron,&nbsp;Robert L Page","doi":"10.1515/dmdi-2012-0033","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Acute muscle injury and potentially fatal rhabdomyolysis may occur with use of statins and certain interacting medications. This investigation assessed risk for myopathy in patients receiving treatment with a statin in combination with daptomycin, a medication also associated with muscle injury.</p><p><strong>Methods: </strong>Patients hospitalized from July 1, 2005, through June 30, 2010, who received simvastatin or rosuvastatin concurrently with daptomycin were identified and their medical records were examined. Patients were judged to have treatment-related muscle injury if their records contained evidence of myalgia with or without weakness and secondarily impaired mobility together with elevated creatine kinase (CK) levels. These assessments were compared with similar data from hospitalized patients who received a statin alone.</p><p><strong>Results: </strong>A total of 52 patients received 66 courses of concurrent treatment with simvastatin or rosuvastatin and daptomycin. Of these, no patient (0%) met evidentiary requirements for diagnosis of myopathy or related complications. No patient (0%) developed muscle pain or discomfort and none developed markedly elevated CK levels. The incidence of asymptomatic elevations of CK in these simvastatin or rosuvastatin plus daptomycin recipients (9%) was statistically indistinguishable from the incidence of CK elevations found in a cohort of 105 inpatients who received simvastatin or rosuvastatin alone (21%; p=0.135).</p><p><strong>Conclusions: </strong>In patients receiving treatment with simvastatin or rosuvastatin and daptomycin, no symptoms or objective evidence of muscle injury attributable to a drug interaction were identified. These findings are consistent with data indicating that the myopathic effects of statins and daptomycin are incited by disparate and perhaps unique pharmacological mechanisms. Risk of muscle injury therefore appears to be no greater when a statin is administered with daptomycin than when either medication is used alone.</p>","PeriodicalId":11319,"journal":{"name":"Drug Metabolism and Drug Interactions","volume":"28 1","pages":"49-58"},"PeriodicalIF":0.0000,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/dmdi-2012-0033","citationCount":"20","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Metabolism and Drug Interactions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/dmdi-2012-0033","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 20

Abstract

Background: Acute muscle injury and potentially fatal rhabdomyolysis may occur with use of statins and certain interacting medications. This investigation assessed risk for myopathy in patients receiving treatment with a statin in combination with daptomycin, a medication also associated with muscle injury.

Methods: Patients hospitalized from July 1, 2005, through June 30, 2010, who received simvastatin or rosuvastatin concurrently with daptomycin were identified and their medical records were examined. Patients were judged to have treatment-related muscle injury if their records contained evidence of myalgia with or without weakness and secondarily impaired mobility together with elevated creatine kinase (CK) levels. These assessments were compared with similar data from hospitalized patients who received a statin alone.

Results: A total of 52 patients received 66 courses of concurrent treatment with simvastatin or rosuvastatin and daptomycin. Of these, no patient (0%) met evidentiary requirements for diagnosis of myopathy or related complications. No patient (0%) developed muscle pain or discomfort and none developed markedly elevated CK levels. The incidence of asymptomatic elevations of CK in these simvastatin or rosuvastatin plus daptomycin recipients (9%) was statistically indistinguishable from the incidence of CK elevations found in a cohort of 105 inpatients who received simvastatin or rosuvastatin alone (21%; p=0.135).

Conclusions: In patients receiving treatment with simvastatin or rosuvastatin and daptomycin, no symptoms or objective evidence of muscle injury attributable to a drug interaction were identified. These findings are consistent with data indicating that the myopathic effects of statins and daptomycin are incited by disparate and perhaps unique pharmacological mechanisms. Risk of muscle injury therefore appears to be no greater when a statin is administered with daptomycin than when either medication is used alone.

他汀类药物和达托霉素:同时使用的安全性评估和药物相互作用责任的评价。
背景:使用他汀类药物和某些相互作用的药物可能发生急性肌肉损伤和潜在致命的横纹肌溶解。这项研究评估了接受他汀类药物与达托霉素联合治疗的患者发生肌病的风险,达托霉素也是一种与肌肉损伤相关的药物。方法:选取2005年7月1日至2010年6月30日住院的辛伐他汀或瑞舒伐他汀与达托霉素同时使用的患者,并对其病历进行分析。如果患者的记录包含肌痛伴或不伴虚弱、继发性活动能力受损以及肌酸激酶(CK)水平升高的证据,则判断患者患有治疗相关性肌肉损伤。这些评估与单独接受他汀类药物治疗的住院患者的类似数据进行了比较。结果:52例患者共接受了66个疗程的辛伐他汀或瑞舒伐他汀联合达托霉素治疗。其中,没有患者(0%)符合诊断肌病或相关并发症的证据要求。没有患者(0%)出现肌肉疼痛或不适,也没有患者出现CK水平明显升高。在接受辛伐他汀或瑞舒伐他汀联合达托霉素治疗的患者中,无症状性CK升高的发生率(9%)与单独接受辛伐他汀或瑞舒伐他汀治疗的105例住院患者的CK升高发生率(21%;p = 0.135)。结论:在接受辛伐他汀或瑞舒伐他汀联合达托霉素治疗的患者中,没有发现药物相互作用导致肌肉损伤的症状或客观证据。这些发现与数据一致,表明他汀类药物和达托霉素的肌病作用是由不同的,也许是独特的药理学机制引起的。因此,当他汀类药物与达托霉素联合使用时,肌肉损伤的风险似乎并不比单独使用任何一种药物时更大。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信